IL-6

Biomarker data on Ph2 Affinity Study (Gus+Gol vs Gus) in PsA Combi Gus+Gol and mono Gus significantly reduced sIL-17A/F & BD2 levels Gus+Gol decr CRP, IL-6 & TNG activity thru wk 24 @RheumNow #ACR26 Abs2943 https://t.co/n1dxn0EREy

Novel therapy for FMF! Goflikicept (GOF) is a potent inhibitor of IL-1β w/ some binding to IL-1α + IL-1RA. RCT of GOF vs placebo in 33 colchicine refractory FMF pts achieved primary endpoint of complete response @ 16W, 68% vs 11%. Abstract 1881 #ACR26 @RheumNow

#ACR26 @RheumNow Probiotics/synbiotics in RA trials -3 trials, 46 to 60 patients, 8 wks All showed improvements of DAS28, VAS pain, hs-CRP, TNF, IL12, but only 1 w/ clinically meaningful response -2 negative trials. No signif benefit in ACR20, DAS28 https://t.co/01h0sR6c9d

Maslyanskiy et al. PROMISE trial in PMR. IL-6i olokizumab. @RheumNow #ACR26 Abstr#1127 https://t.co/4xVUuPtsmr

https://x.com/RichardPAConway/status/2119816783804895532/photo/1

Early tocilizumab leads to less hospitalization in #GCA. TriNetX study of 127 GCA Rx (w/in 3 mos Dx) w/ TCZ+GC vs GC alone (127). Early TCZ had 36% less hosp in 12 mos (19.7 vs 30.7%) but no diff in vascular events. Abstract #166 #ACR26 https://t.co/a9WfEMQ8wg https://t.co/ors9EBYb6T

Early Tocilizumab Initiation and 12-Month Hospitalisation in Giant Cell Arterit…

Impt pathway for #fibrosis & #inflammation? FIbrosis in #sarcoidosis mediated thru #TL1A Myeloid cells —granulomas TL1A effects TNF IL1beta IL6 IL17 Drugs could be effective Some already in #IBD Ex #Tulisokibart #Duvakitug #Afimkibart 🤷 #O019 #ACR26 @RheumNow @ACRheum https://t.co/GPKwEqWFkh

https://x.com/Janetbirdope/status/2119597674567496020/photo/1

MTX hold 2 wk after each RZV dose: better T-cell response RCT substudy, n=38, stable ARD gE CD4 responders 65→95% hold vs 61→67% continue (p=0.038) IL-2/TNF-α driven Reasonable in stable pts. Wait for a bigger trial. ＠RheumNow #ACR26 Abstr#0899 https://t.co/4bobGIAuZX

https://x.com/he67407/status/2119540249001095191/photo/1

SUNSTAR (n=224): first head-to-head trial of 2 non-TNFi bDMARDs. SC tocilizumab did not demonstrate superiority to abatacept on week-26 CDAI change. A secondary composite response favoured tocilizumab (51% vs 36%); more infections reported. #0468 #ACR26 @Rheumnow https://t.co/TbRvR2qUZf

https://x.com/DrMiniDey/status/2119494157869679087/photo/1

Schönau et al. GCA in imaging free (PET and US) remission following tocilizumab withdrawal (>6 months). >50% flare within 72 weeks. @RheumNow #ACR26 Abstr#186 https://t.co/dW8aGJ0GR1

https://x.com/RichardPAConway/status/2119471760395444678/photo/1

Kreis et al. What to do after tocilizumab in GCA. MTX did not reduce time to relapse. Few secondary outcomes numerically lower with MTX. In my opinion, just continue the tocilizumab. @RheumNow #ACR26 Abstr#0179 https://t.co/E3uOnaxPmW

https://x.com/RichardPAConway/status/2119468740710404487/photo/1

Chevet et al. GCA with normal CRP. It does exist and is different, with higher ischaemic risk than standard GCA. Tocilizumab remains highly effective. @RheumNow #ACR26 Abstr#0172 https://t.co/g53Gw71xiQ

https://x.com/RichardPAConway/status/2119460184276045910/photo/1

Schmidt @Janetbirdope et al. Post-hoc SAPHYR analysis showed significantly higher remission when sarilumab was initiated within 6 months of PMR onset @RheumNow #ACR26 Abstr#0167 https://t.co/b0xPwYK0E5

https://x.com/RichardPAConway/status/2119458925632446491/photo/1

Patel et al. Early tocilizumab use in GCA associated 36% relative reduction in acute care encounters in 1 year compared to steroid monotherapy. @RheumNow #ACR26 Abstr#0166 https://t.co/4OrWljzFXp

https://x.com/RichardPAConway/status/2119458170750046458/photo/1

Can we eliminate pathogenic T cells while preserving overall T-cell counts? #ACR26 Abst 0868: Rosnilimab depleted >90% of PD-1high pathogenic T cells, downregulating synovial IL-6, TNF & IFN pathways. A new paradigm in RA? @RheumNow https://t.co/AQbDLy0Iox

Does IL-5 therapy work for EGPA vasculitic manifestations? Abst0214 details EGPA pts based on hx vasculitic disease and use of IL-5 alone vs. with other IS Comparable vasculitic recurrence in those with hx Higher new-onset vasculitic disease in IL-5 only #ACR26 @RheumNow https://t.co/0lW6eqy3sb

https://x.com/Dr_Brian_MD/status/2119446937183363224/photo/1

We should be using steroid-sparing therapy in PMR EARLY!! Analysis of SAPHYR: better response to Sarilumab compared to PBO extinguished in patients with disease longer than a year A similar trend was observed in a comparative real world data set Abst0167 @Rheumnow #ACR26 https://t.co/OO5Nv3DJZd

https://x.com/Dr_Brian_MD/status/2119433021283512540/photo/1

Basic Sci Yr in Rvw #ACR26 Pyrin ligand: CDC42 binds B30.2 MEFV gene in Med Fever lie in B30.2 CDC42-opathy joins IL-1 responsive autoinflamm diseases VEXAS- 2 mech from UBA1 Met41 mutations 1. Mutant macrophages die by apoptosis, necroptosis 2. Unfolded prot response @RheumNow https://t.co/ki1jSZnJIu

Treatment for ICI-IrAEs: •Early immunosuppression/high doses of steroids (first 2 months) associated with worse survival. •ICI-IA: TNFi and IL-6Ri mostly used •ICI-PMR: steroids/IL6Ri •ICI-myositis: steroids/IVIG mostly used. •Little data on effects of long-term

After stopping TCZ in GCA (~2 yrs exposure), over HALF of pts still flared w/in 72 weeks, even among pts w/imaging remission Most flares 3-6 mos post stopping Good evidence for continuing longer; I continue many pts on TCAZ up to 5 years post dx @RheumNow #ACR26 Ab#0186 https://t.co/yq0rXv1l3S

https://x.com/EBRheum/status/2119102074457919768/photo/1

Tocilizumab is effective in glucocorticoid-resistant adult-onset Still’s dz. 40 AOSD pts rx w/ TCZ (4-8 mg/kg q4wks). @12 mos clin remission 55%, 6 mos CID 62%, signif drops in CRP, ESR, ferritin & daily pred decr 91% (50 to 4.4 mg; p<0.001). TCZ retention 65%; MAS 7.5% & https://t.co/Olynr7VfhE

Japanese retrospective cohort systemic sclerosis study shows adjunctive tofacitinib improved ower esophageal sphincter pressures (LESP). 50 SSc pts w/ esophageal Sxs Rx w/ Tofa or PBO x 24 wks. Tofa assoc w/ signif LESP increases & lower mRSS & IL-6 levels https://t.co/NNREBddiOi https://t.co/acVOfoorRP

Tofacitinib and esophageal-related manifestations in systemic sclerosis: a retr…

Article

3 x IL-23 = IL do Better (11.6.2026)

Jack Cush, MD Nov 06, 2026

Dr. Jack Cush reviews the FDA approvals and news reports from this past week on RheumNow.com. This week we discuss playing the numbers in rheumatology, playing the long game with stem cell transplants, and a=the Positive spin on seronegative RA.

Tocilizumab is effective in glucocorticoid-resistant adult-onset Still’s dz. 40 AOSD pts rx w/ TCZ (4-8 mg/kg q4wks). @12 mos clin remission 55%, 6 mos CID 62%, signif drops in CRP, ESR, ferritin & daily pred decr 91% (50 to 4.4 mg; p<0.001). TCZ retention 65%; MAS 7.5% & https://t.co/jtAxrz6ETd

Japanese retrospective cohort systemic sclerosis study shows adjunctive tofacitinib improved ower esophageal sphincter pressures (LESP). 50 SSc pts w/ esophageal Sxs Rx w/ Tofa or PBO x 24 wks. Tofa assoc w/ signif LESP increases & lower mRSS & IL-6 levels https://t.co/NNREBddiOi https://t.co/p6VujI8HWA

Tofacitinib and esophageal-related manifestations in systemic sclerosis: a retr…

Takayasu Arteritis: Do TNFis or IL-6- inhibitors come out on top? The treatment of active TAK is imperative to quiet vascular inflammation and subsequently maintain vascular integrity while preventing vessel damage. https://t.co/J1EQHGzR5O https://t.co/i59kRGJCoK

Takayasu Arteritis: Do TNFis or IL-6- inhibitors come out on top? | RheumNow

Topics

3 x IL-23 = IL do Better (11.6.2026)

Daily Download

Scope of Infections Associated with b/ts DMARDs

Topic Videos

Do you get our email newsletter?